Cargando…
Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study
AIM: To evaluate effectiveness of dexamethasone intravitreal implant 0.7 mg (DEX) monotherapy in the AUSSIEDEX study non-responder subgroup, defined by diabetic macular oedema (DME) refractory to anti-vascular endothelial growth factor (anti-VEGF) agents. METHODS: This prospective, open-label, obser...
Autores principales: | Mitchell, Paul, Arnold, Jennifer, Fraser-Bell, Samantha, Kang, Hyong Kwon, Chang, Andrew A, Tainton, Jodi, Simonyi, Susan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407411/ https://www.ncbi.nlm.nih.gov/pubmed/37541745 http://dx.doi.org/10.1136/bmjophth-2022-001224 |
Ejemplares similares
-
Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study
por: Fraser-Bell, Samantha, et al.
Publicado: (2023) -
Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice
por: Gurung, Rajya L, et al.
Publicado: (2021) -
Controlled Release of Dexamethasone From an Intravitreal Delivery System Using Porous Silicon Dioxide
por: Hou, Huiyuan, et al.
Publicado: (2016) -
Turnover of Microaneurysms After Intravitreal Injections of Faricimab for Diabetic Macular Edema
por: Takamura, Yoshihiro, et al.
Publicado: (2023) -
Serum apolipoprotein A1 and B are associated with 6-month persistent and incident diabetic macular oedema in type 2 diabetes
por: Soedarman, Soefiandi, et al.
Publicado: (2023)